Oct 4
ABS, a leading innovator in global bovine genetics, is proud to announce it is taking full ownership of De Novo Genetics LLC, the ABS dairy genetics nucleus. This major strategic investment marks a significant milestone in the company’s growth and will pave the way for greater innovation, product validation, and genetic development through acquiring total control of its dairy genetics engine.
Established in 2016 as a joint venture between ABS and De-Su Holsteins of New Albin, Iowa, De Novo has successfully developed more than 800 dairy bulls that have been introduced into the market through ABS or are awaiting launch. This impressive lineup includes renowned daughter-proven sires like ENTITY and VENTURE, alongside impactful young bulls such as BENEFIT and LEEDS. Most significantly, the highest quality De Novo genetics are still in the young-bull pipeline at ABS, poised to provide even greater results.
“We would like to thank Darin and the entire Meyer family for their great partnership and strong support over these years and wish them continued success as we work together in the future,” says Katie Olson, ABS Senior Director, Global Bovine Product Development.
The focus on De Novo underpins ABS’ commitment to dairy customers.
“We are excited to take full control of De Novo, which is a critical component of our long-term product strategy,” adds Jim Low, ABS COO. “This investment enables us to deliver on our commitment to excellence, allowing us to innovate faster, improve quality, and respond effectively to the needs of our customers. Our team is already working on new features and improvements that will set De Novo apart in the market.”
Looking forward, most ABS embryo donors will be housed at ABS facilities, along with third-party facilities such as De-Su Holsteins. Thousands of ET and IVF calves will continue to be born each year at a growing alliance of cooperator recipient herds.
The full ownership of De Novo reflects ABS’s dedication to leading the industry with cutting-edge genetics that set new standards. Customers can expect continued rapid genetic improvement, product diversity and traits that enhance profitability as ABS pushes the boundaries of what’s possible with De Novo.
In addition to technological advancements, the investment underscores the company’s confidence in the future of De Novo as a critical part of its product portfolio. It also ensures that ABS maintains complete control over the direction and vision for De Novo, safeguarding the product’s roadmap and maintaining alignment with the company’s strategic objectives.
Media Contact:
Elizabeth Sheppard, ABS Global Communications Manager [email protected]
About ABS Global
Headquartered in DeForest, Wisconsin, USA, ABS Global is the world-leading provider of bovine genetics, reproduction services, technologies, and udder care products. Marketing in more than 70 countries around the globe, ABS has been at the forefront of animal genetics and technology since its founding in 1941. In bovine genetics, ABS serves more than 40,000 customers globally, including some of the world’s leading beef and dairy producers. ABS Global owns bull studs in Europe, North America, Latin America, and India, selling genetics to dairy and beef customers in North America, Latin America, Asia and Europe. ABS Global is a division of Genus plc.